

# Justin R Lenhard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3626588/publications.pdf>

Version: 2024-02-01

22  
papers

575  
citations

687363

13  
h-index

677142

22  
g-index

22  
all docs

22  
docs citations

22  
times ranked

799  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interaction of <i>Staphylococcus aureus</i> and <i>Acinetobacter baumannii</i> during <i>In Vitro</i> $\beta$ -Lactam Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	10
2	Losing the Battle but Winning the War: Can Defeated Antibacterials Form Alliances to Combat Drug-Resistant Pathogens?. <i>Antibiotics</i> , 2021, 10, 646.	3.7	5
3	Capability of <i>Enterococcus faecalis</i> to shield Gram-negative pathogens from aminoglycoside exposure. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2610-2614.	3.0	3
4	A coup d'État by NDM-producing <i>Klebsiella pneumoniae</i> overthrows the major bacterial population during KPC-directed therapy. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 98, 115080.	1.8	3
5	Bacterial brothers in arms: cooperation of <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i> during antimicrobial exposure. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2657-2665.	3.0	12
6	Inoculum effect of $\beta$ -lactam antibiotics. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2825-2843.	3.0	83
7	Shifting Gears: The Future of Polymyxin Antibiotics. <i>Antibiotics</i> , 2019, 8, 42.	3.7	20
8	Impact of <i>Staphylococcus aureus</i> accessory gene regulator ( <i>agr</i> ) system on linezolid efficacy by profiling pharmacodynamics and RNAIII expression. <i>Journal of Antibiotics</i> , 2017, 70, 98-101.	2.0	2
9	Influence of <i>rhlR</i> and <i>lasR</i> on Polymyxin Pharmacodynamics in <i>Pseudomonas aeruginosa</i> and Implications for Quorum Sensing Inhibition with Azithromycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	13
10	High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant <i>Acinetobacter baumannii</i> in a Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	60
11	Pharmacodynamics of colistin and fosfomycin: a "treasure trove" combination combats KPC-producing <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1985-1990.	3.0	43
12	Polymyxin-resistant, carbapenem-resistant <i>Acinetobacter baumannii</i> is eradicated by a triple combination of agents that lack individual activity. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1415-1420.	3.0	44
13	<i>In vitro</i> pharmacodynamic evaluation of ceftolozane/tazobactam against $\beta$ -lactamase-producing <i>Escherichia coli</i> in a hollow-fibre infection model. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 25-30.	2.5	8
14	High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in <i>Acinetobacter baumannii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 153-165.	3.0	36
15	Defining the Active Fraction of Daptomycin against Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach. <i>PLoS ONE</i> , 2016, 11, e0156131.	2.5	5
16	Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3913-3920.	3.2	43
17	Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant <i>Acinetobacter baumannii</i> . <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 719-724.	2.5	14
18	Synergistic combinations of polymyxins. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 607-613.	2.5	71

#	ARTICLE	IF	CITATIONS
19	Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in <i>Staphylococcus aureus</i> : Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1584-1591.	3.2	18
20	Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined $\beta$ -Lactamase-Producing <i>Escherichia coli</i> : Insights into the Pharmacokinetics/Pharmacodynamics of $\beta$ -Lactamase- $\beta$ -Lactamase Inhibitor Combinations. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1967-1973.	3.2	11
21	Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria. <i>Infectious Diseases and Therapy</i> , 2015, 4, 391-415.	4.0	45
22	Evolution of <i>Staphylococcus aureus</i> under Vancomycin Selective Pressure: the Role of the Small-Colony Variant Phenotype. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1347-1351.	3.2	26